Tomographic Findings in COVID-19 and Influenza H1N1

NCT ID: NCT04499378

Last Updated: 2021-05-03

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-08-15
• Study Completion Date: 2022-04-30

Brief Summary

The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to evaluate the association between the radiological CT pattern and the need for invasive mechanical ventilation. A secondary aim is to assess the mortality within the first 28 days of intensive care unit admission.

Detailed Description

Background In late 2019, a new coronavirus was linked to several cases of pneumonia in the city of Wuhan, Hubei province, China. On February 11, 2020, the World Health Organization (WHO) designated COVID-19 a pandemic disease. The mortality associated with COVID-19 patients that required management in a critical care unit is approximately 4.3%. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnosis of COVID-19 is made with a positive test (i.e. reverse transcriptase-polymerase chain reaction, RT-PCR) from a person with clinical signs and symptoms of a respiratory tract infection. Viral pneumonia is currently a challenge worldwide as it is associated with high morbidity and mortality. In June of 2009, the WHO declared influenza A H1N1 a pandemic disease. Worldwide, influenza H1N1 had a mortality of 11%, with a higher mortality rate among people older than 50 years of age (i.e. 18-20%). Influenza diagnosis can be established using RT-PCR. Around 200 million cases of community-acquired viral pneumonia occur each year worldwide, 100 million in children, and 100 million in adults. Imaging findings in viral pneumonia are diverse and overlap with findings associated with non-viral infections and inflammatory conditions. However, identifying the underlying viral pathogens may not always be easy. Several imaging patterns have been described in association with these viruses. Although a definitive diagnosis cannot be achieved based on imaging studies, imaging pattern recognition of viral pneumonia can help differentiate between viral and bacterial pathogens; thus, reducing the use of indiscriminate antibiotics. Few studies correlate tomographic findings in patients with viral infections in the lower respiratory tract.

The use of computed tomography (CT) should be considered as the first option for diagnostic imaging in patients with suspected pneumonia. Peripheral multifocal ground glass patterns with irregular consolidation images found in the lower lobes or posteriorly in pulmonary CT scans have been described in patients with viral pneumonia due to SARS-CoV-2. Furthermore, complicating the diagnosis of atypical viral pneumonia, 17.9% of mild COVID-19 and 2.9% of moderate-severe COVID-19 patients did not have CT evidence of pneumonia upon hospital admission. One recent study compared the CT radiological patterns found in COVID-19 pneumonia to other viral pneumonias (i.e. influenza, parainfluenza, adenovirus, and respiratory syncytial virus) reporting higher peripheral distribution (i.e. 80% vs. 57%, p<0.001), more ground-glass opacities (i.e. 91% vs 68%, p<0.001), greater frequency of fine reticular opacities (i.e. 56% vs. 22%, p<0.001), and vascular thickening in COVID-19 patients; meanwhile, other viral pneumonias were more likely to have a mixed distribution pattern(i.e. 35% vs. 14%, p<0.001), have pleural effusion (i.e. 39% vs. 4.1%, p<0.001), and present visible lymph nodes (10.2% vs. 2.7%, p<0.001). Another study compared the pulmonary radiological patterns associated with COVID-19 compared to influenza (A and B) reporting higher round opacities (i.e. 35% vs. 17%, p=0.048) and greater frequency of interlobular septal thickening (i.e. 66% vs. 43%, p=0.014) in patients with COVID-19; conversely, influenza patients had a higher frequency of nodular lesions (i.e. 71% vs. 28%, p<0.001), higher frequency of small dense nodular lesions (i.e. 40% vs. 9%, p<0.001), and more likely to have pleural effusion (i.e. 31% vs. 6%, p<0.001).

Research questions

1. What are the pulmonary tomographic findings in patients diagnosed with community-acquired pneumonia secondary to SARS-CoV-2?

2. What are the pulmonary tomographic findings in patients diagnosed with community-acquired pneumonia secondary to H1N1 influenza?

3. Is there a difference among lung CT radiological patterns in patients with pneumonia secondary to SARS-CoV-2 and its association with the need for invasive mechanical ventilation?

4. Is there a difference among lung CT radiological patterns in patients with pneumonia secondary to H1N1 influenza and its association with the need for invasive mechanical ventilation?

5. Is there a difference between groups (i.e. SARS-CoV-2 versus H1N1 influenza) and its association with the need for the use of invasive mechanical ventilation?

6. Are the 28-day survival distributions different for SARS-CoV-2 and H1N1 influenza?

7. Is there a difference in the 28-day survival distribution and the pulmonary tomographic radiological patterns in patients with pneumonia secondary to SARS-CoV-2?

8. Is there a difference in the 28-day survival distribution and the pulmonary tomographic radiological patterns in patients with pneumonia secondary to H1N1 influenza?

9. What factors are associated with the survival differences in 28-day mortality in both groups and between groups?

Aims Primary aim: Compare pulmonary tomographic findings of patients diagnosed with SARS-CoV-2 and H1N1 influenza pneumonia patients at Hospital General Regional Leon IMSS no. 58.

Secondary aims

• Identify pulmonary CT radiological patterns in patients diagnosed with SARS-CoV-2 pneumonia.
• Identify pulmonary CT radiological patterns in patients diagnosed with influenza H1N1 pneumonia.
• Identify the association between CT patterns of patients diagnosed with SARS-CoV-2 or H1N1 influenza pneumonia who require invasive mechanical ventilation.
• Identify the CT patterns of SARS-CoV-2 and H1N1 influenza patients that are associated with 28-day mortality.

Statistical analysis No literature is available to calculate the primary objective (i.e. measure the frequency of radiological patterns associated with viral pneumonia secondary to SARS-CoV-2 and H1N1 influenza) or for the secondary objective (risk of intubation) this study will serve as a pilot study for the calculation of samples in future research projects. A sample calculation was performed to determine statistically significant differences in the outcome of radiological patterns secondary to H1N1 influenza. The sample size was calculated based on the proportions reported by Jartti et al. (2011). The sample size was calculated to detect statistically significant differences taking as parameters an α = 0.05 and statistical power of 0.8 (i.e. 1-β). The calculator was used to calculate sample sizes based on proportions of two samples considering the equality of the two extremes (i.e. one Gaussian distribution tail), available on the website: http://powerandsamplesize.com/. The parameters are as follows: nA, number of patients with H1N1 influenza in the reference study (i.e. 159); nB, number of patients with H1N1 influenza pneumonia; pA, frequency of patients with radiological consolidation data, in percentage, for previously reported H1N1 influenza patients (i.e. 93%); pB, frequency of patients with radiological consolidation syndrome, in percentage, in patients with H1N1 influenza pneumonia in our population (i.e. H0: probability = 0.5); k, sampling ratio (i.e. 1: 1). Considering the results, we consider that a sample greater than 23 patients with H1N1 influenza pneumonia is necessary to detect differences in radiological patterns in patients with viral pneumonia.

Conditions

Covid19; Influenza A H1N1; Intubation Complication; Morality; Lung Injury, Acute

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

SARS-CoV-2

Patients with a positive SARS-CoV-2 PCR test upon admission to the emergency department.

Lung CT

Intervention Type: DIAGNOSTIC_TEST

Computed tomography of the thorax

H1N1 influenza

Patients with a positive Influenza H1N1 PCR test upon admission to the emergency department.

Lung CT

Intervention Type: DIAGNOSTIC_TEST

Computed tomography of the thorax

Interventions

Lung CT

Computed tomography of the thorax

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Patients with signed informed consent.
• Patients with a positive PCR test for SARS-CoV-2 or influenza H1N1 test upon emergency department admission.
• Patients with lung CT within 24hrs of specimen collection for PCR test.
• Patients with complete 30-day follow-up information.

Exclusion Criteria

• Patients who are unwilling to undergo a lung CT.
• Negative PCR test for SARS-CoV-2 or influenza H1N1 test upon emergency department admission.
• Patients with a tumor or tumor metastasis on the pulmonary CT.
• Patients with a previous or de novo autoimmune disease diagnosis.
• Patients with a previous or de novo interstitial lung disease.
• Pregnancy.

Elimination Criteria:

• Patients with loss of information on the variables of interest.
• Patients without 30-day follow-up information.
• Patients who chose to withdraw their participation at any time of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Medical Center Groningen

OTHER

Sponsor Role: collaborator

Universidad de Guanajuato

OTHER

Sponsor Role: lead

Responsible Party

Jaime Daniel Mondragón Uribe

Medical researcher

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jaime D Mondragon, M.D.

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Groningen

Omar Jiménez-Zarazúa, M.D.

Role: PRINCIPAL_INVESTIGATOR

Universidad de Guanajuato

Locations

Hospital General Regional Leon Imss N0. 58

León, Guanajuato, Mexico

Site Status: RECRUITING

Countries

Mexico

Central Contacts

Omar Jiménez-Zarazúa, M.D.

Role: CONTACT

drzarazuainterna@hotmail.com

+52-442-1377672

Facility Contacts

Omar Jimenez-Zarazua, MD

Role: primary

drzarazuainterna@hotmail.com

52 477 101 5110

Bertha I Arevalo-Rivas, MD

Role: backup

barevalo@ugto.mx

52 477 101 5110

References

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

Reference Type: RESULT

PMID: 32031570 (View on PubMed)

Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med. 2018 Aug;66(6):957-965. doi: 10.1136/jim-2018-000712. Epub 2018 Apr 20.

Reference Type: RESULT

PMID: 29680828 (View on PubMed)

Fineberg HV. Pandemic preparedness and response--lessons from the H1N1 influenza of 2009. N Engl J Med. 2014 Apr 3;370(14):1335-42. doi: 10.1056/NEJMra1208802. No abstract available.

Reference Type: RESULT

PMID: 24693893 (View on PubMed)

Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D; California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009 Nov 4;302(17):1896-902. doi: 10.1001/jama.2009.1583.

Reference Type: RESULT

PMID: 19887665 (View on PubMed)

Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):e1-e47. doi: 10.1093/cid/ciy866.

Reference Type: RESULT

PMID: 30566567 (View on PubMed)

Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011 Apr 9;377(9773):1264-75. doi: 10.1016/S0140-6736(10)61459-6. Epub 2011 Mar 22.

Reference Type: RESULT

PMID: 21435708 (View on PubMed)

Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT Features of Viral Pneumonia. Radiographics. 2018 May-Jun;38(3):719-739. doi: 10.1148/rg.2018170048.

Reference Type: RESULT

PMID: 29757717 (View on PubMed)

Shiley KT, Van Deerlin VM, Miller WT Jr. Chest CT features of community-acquired respiratory viral infections in adult inpatients with lower respiratory tract infections. J Thorac Imaging. 2010 Feb;25(1):68-75. doi: 10.1097/RTI.0b013e3181b0ba8b.

Reference Type: RESULT

PMID: 20160606 (View on PubMed)

Upchurch CP, Grijalva CG, Wunderink RG, Williams DJ, Waterer GW, Anderson EJ, Zhu Y, Hart EM, Carroll F, Bramley AM, Jain S, Edwards KM, Self WH. Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs: Pathogens, Severity, and Clinical Outcomes. Chest. 2018 Mar;153(3):601-610. doi: 10.1016/j.chest.2017.07.035. Epub 2017 Aug 9.

Reference Type: RESULT

PMID: 28802696 (View on PubMed)

Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. Epub 2020 Feb 21.

Reference Type: RESULT

PMID: 32083985 (View on PubMed)

Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, Pan I, Shi LB, Wang DC, Mei J, Jiang XL, Zeng QH, Egglin TK, Hu PF, Agarwal S, Xie FF, Li S, Healey T, Atalay MK, Liao WH. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. Radiology. 2020 Aug;296(2):E46-E54. doi: 10.1148/radiol.2020200823. Epub 2020 Mar 10.

Reference Type: RESULT

PMID: 32155105 (View on PubMed)

Liu M, Zeng W, Wen Y, Zheng Y, Lv F, Xiao K. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-5469. doi: 10.1007/s00330-020-06928-0. Epub 2020 May 12.

Reference Type: RESULT

PMID: 32399710 (View on PubMed)

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.

Reference Type: RESULT

PMID: 32109013 (View on PubMed)

Other Identifiers

F-2020-1008-038

Identifier Type: -

Identifier Source: org_study_id